-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

285 Lovesick: Examining Couples Health during Myeloma Transplant

Program: Oral and Poster Abstracts
Type: Oral
Session: 907. Outcomes Research: Plasma Cell Disorders: Quality Matters and Key Outcomes in Multiple Myeloma
Hematology Disease Topics & Pathways:
Research, Clinical Research, Health outcomes research, Patient-reported outcomes
Saturday, December 7, 2024: 2:30 PM

Ashley Rosko, MD1, Don Benson, MD1, Francesca Cottini, MD1,2, Abdullah Mohammad Khan, MD, MBBS1,3,4,5, Srinivas Devarakonda, MD1,6,7, Elvira Umyarova, MD8, Naresh Bumma, MD4,5,9, Lisa Blackburn10*, Cathie Atkinson11*, Juan Peng12*, Janice Kiecolt-Glaser13* and Lisa Christian14*

1The Ohio State University, Columbus, OH
2Department of Internal Medicine, Division of Hematology, The Ohio State University, Columbus, OH
3US Myeloma Innovations Research Collaborative (USMIRC), Kansas City, KS
4Division of Hematology, The Ohio State University Comprehensive Cancer Center, Columbus, OH
5The Ohio State University Comprehensive Cancer Center, Columbus, OH
6Division of Hematology, Department of Internal Medicine, Ohio State University Medical Center, Columbus, OH
7Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH
8The Ohio State University Wexner Medical Center, Columbus, OH
9The Ohio State University, COLUMBUS, OH
10The Ohio State University, College of Medicine, Columbus
11Institute for Behavioral Medicine Research, Ohio State University, Columbus, OH
12Depart of Medicine, Center for Biostatistics, Ohio State University, Columbus, OH
13Department of Medicine-Psychiatry, Ohio State University, Columbus, OH
14Depart of Medicine-Psychiatry, Ohio State University, Columbus, OH

Introduction: Couples mutually influence one another’s’ physical and mental health trajectories, however a cancer diagnosis disrupts that connection. Multiple Myeloma (MM) is an incurable cancer, and patients remain on treatment indefinitely; thus patients and their spousal/partners face substantial long-term challenges including poor physical functioning, frailty, and emotional distress. Both patients and their spouse/partners have increased risk for heightened depressive and anxiety symptoms. Depression in MM patients has been reliably associated with poorer outcomes including greater 1-year post-Autologous Stem Cell Transplant (ASCT) mortality, and worse overall survival. Spouses/partners play a central role in the peri-ASCT preparation and recovery, and thus it is concerning that spouse/partner anxiety and depression often exceed that of patients. Here we examine the extent to which physical function, frailty, HRQoL and psychological distress, are interconnected among MM patients and their spouse/partner, as dyads, before and after MM ASCT.

Methods: Dyads (MM patients and spouse/partners) were enrolled in a prospective longitudinal study; assessments were administered prior to and post-ASCT at 90 days and 1 year. Measures included the Fried frailty phenotype, functional impairment [Short Physical Performance Battery (SPPB)], distress (Impact of Event Scale-Revised), depression [Center for Epidemiologic Studies Depression (CES-D)], couples’ satisfaction index (CSI-16), spousal strain (MIDUS), self-reported health [Karnofsky Performance Status (KPS) self), PROMIS HRQoL (Global 10, fatigue) were measured.

Results: Among dyads (n=62), pre-ASCT discordance in health measures (SPPB, IADL, fatigue, frailty) were evident with concordance among only social support (r=0.37, p=0.04) and self-reported health (KPS self, r=-0.41, p=0.02). Age was associated with lower functional scores [SPPB ß=-0.03 (SE:0.016), p=0.04] and men had greater changes in function peri-transplant [SPPB ß=0.92 (SE:0.329), p<0.01] compared to women. Among MM pts depression symptoms (CES-D) were significantly (p<0.01) associated with frailty (ß=0.05), and HRQoL (PROMIS Fatigue ß=0.61, PROMIS Global ß=-0.44) before and after transplant (not shown). The average distress effect on frailty was significant across groups. However, the distress effect in pts (ß=0.027 (SE: 0.008), p=0.0017) was greater than spouses (ß=0.003 (SE: 0.0096), p=0.77). ] Pre-ASCT, average couple satisfaction effect on self-reported health was significant (p=0.05), however the couple satisfaction effect was greatest in spouses [ß=0.49 (SE:0.121), p=<0.01]. Couples’ satisfaction was associated with improved physical function [SPPB ß=0.04 (SE:0.0213), p=0.05] pre-ASCT. Spousal strain impacted fatigue peri-ASCT [pre ASCT ß=4.44, (SE:2.37), p=0.07; post ASCT ß=3.81, (SE:1.83), p=0.05] and frailty only pre-ASCT [ß=0.52, (SE:0.24), p=0.04].

Conclusions: Physical frailty and psychologic distress are interconnected in MM patients and spouses. Importantly, the supportive role of spouse/partners and a couples’ perceived relationship health also impact MM ASCT recovery. Targeting programs for physical and emotional survivorship are imperative for both MM patient and spouse/partners.

Disclosures: Rosko: Sanofi: Research Funding; Physicians Education Resource LLC: Honoraria; Curio Science: Honoraria; FDA: Consultancy; Clinical Care Options CMM: Honoraria. Cottini: Sanofi: Honoraria, Membership on an entity's Board of Directors or advisory committees. Khan: Amgen: Speakers Bureau; Sanofi: Research Funding, Speakers Bureau; BMS: Research Funding, Speakers Bureau. Devarakonda: Janssen: Other: Advisory board. Bumma: sanofi: Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Janssen: Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Amgen: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau.

*signifies non-member of ASH